Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash & Current Investments (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Cash & Current Investments data on record, last reported at $178.1 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 21.88% year-over-year to $178.1 million; the TTM value through Dec 2025 reached $745.2 million, up 226.9%, while the annual FY2025 figure was $178.1 million, 21.88% down from the prior year.
  • Cash & Current Investments reached $178.1 million in Q4 2025 per ARQT's latest filing, up from $143.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $409.6 million in Q4 2022 and bottomed at $143.9 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $272.7 million, with a median of $275.0 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: surged 394.11% in 2021, then tumbled 56.45% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $387.1 million in 2021, then grew by 5.82% to $409.6 million in 2022, then crashed by 33.63% to $271.9 million in 2023, then decreased by 16.15% to $228.0 million in 2024, then fell by 21.88% to $178.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $178.1 million in Q4 2025, $143.9 million in Q3 2025, and $190.8 million in Q2 2025.